Long-term safety study of etavopivat for sickle cell disease or thalassaemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in a previous etavopivat study and finished at least the treatment period.
- You must have had clear benefits from etavopivat, as decided by your study doctor.
- If your dose was lowered or paused, you need to restart the full dose before joining this study.
- If you take hydroxyurea, crizanlizumab, or L-glutamine powder, you need to be on a stable dose (with possible temporary adjustments for weight, age, or medical reasons).
- You cannot have stopped etavopivat permanently or be on a reduced dose for more than 28 days.
- You cannot be taking certain other medicines (like strong CYP3A4 inducers) 2 weeks before or during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.